Clinical trials: Advanced Digestive System Tumor
Non-small Cell Lung Cancer, Gastric Cancer
A Study of CDX-585 in Patients With Advanced Malignancies
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT05788484
- Testing
- CDX-585
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Celldex Therapeutics
Pancreatic Neoplasms
Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer
Primary Objective: To demonstrate that the addition of oxaliplatin to 5-Fluorouracil (5-FU) and Leucovorin (LV) will improve the Progression-Free Survival (PFS).
- Trial name
- NCT01121848
- Testing
- Leucovorin, OXALIPLATIN, 5-Fluorouracil
- Where
- 15 sites in Canada
- Volunteers
- 108 people
- Sponsor
- Sanofi
Solid Tumors, Hepatocellular Carcinoma (HCC)
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5).
- Conditions
- Solid Tumors, Hepatocellular Carcinoma (HCC), Malignant Melanoma, Pediatric Cancer
- Trial name
- NCT06636435
- Testing
- CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3
- Where
- 5 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Chiome Bioscience Inc.
Mesothelioma, Pancreatic Cancer
A 2-part Phase 1/2 Open-label Trial on ODM-212
An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
- Conditions
- Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
- Trial name
- TEADCO (NCT07563738)
- Testing
- ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel
- Where
- 23 sites in United States, Denmark and 5 more
- Volunteers
- 229 people
- Sponsor
- Orion Corporation, Orion Pharma
Metastatic Cancer, Melanoma
Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
This study evaluated the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced or metastatic cancer
- Conditions
- Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- ConsortiumIO (NCT04208958)
- Testing
- VE800, Nivolumab, Vancomycin Oral Capsule
- Where
- 18 sites in United States
- Volunteers
- 56 people
- Sponsor
- Vedanta Biosciences, Inc.
Colorectal Cancer, Triple Negative Breast Cancer
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: Cohort A: CRC Cohort B: Gastric…
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
- Trial name
- NCT05453825
- Testing
- navicixizumab+paclitaxel, navicixizumab+irinotecan, navicixizumab monotherapy
- Where
- 8 sites in United States
- Volunteers
- 180 people
- Sponsor
- OncXerna Theraputics, Inc.
Colorectal Adenocarcinoma
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
Researchers are looking for a better way to treat people with advanced colorectal cancer. Colorectal cancer (cancer of the colon or rectum) is one of the most common cancers worldwide.
- Trial name
- NCT07811193
- Testing
- VVD-133214, Pembrolizumab
- Where
- 122 sites in United States, Argentina and 20 more
- Volunteers
- 140 people
- Sponsor
- Vividion Therapeutics, Inc.
Hepatocellular Carcinoma, Cholangiocarcinoma
A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1241 in participants with hepatocellular carcinoma, cholangiocarcinoma, gastric cancer…
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03734926
- Testing
- ZSP1241
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
This is a multicenter, open-label, single arm phase II study to evaluate the efficacy and safety of Infigratinib in patients with locally advanced or metastatic GC or GEJ patient with FGFR2 gene amplification, who have failed at…
- Trial name
- NCT06206278
- Testing
- Infigratinib
- Where
- 30 sites in China
- Volunteers
- 6 people
- Sponsor
- LianBio LLC
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Solid Tumor, Adult, Solid Tumor
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
This clinical trial is designed as a multi-center, open-label, dose-escalation, dose-expansion, phase 1 clinical trial and will be evaluating the safety and efficacy of PB101 in patients with advanced solid tumors who have…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06075849
- Testing
- PB101
- Where
- 3 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Panolos Bioscience
Pancreatic Cancer
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
The purpose of this study is to determine whether patients with locally advanced pancreatic cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared to patients who receive standard of care…
- Trial name
- LAPC (NCT01395017)
- Testing
- dasatinib
- Where
- 74 sites in United States, Australia and 13 more
- Volunteers
- 202 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06131840
- Testing
- PF-08046050, bevacizumab, 5-Fluorouracil (5-FU)
- Where
- 48 sites in United States, Canada and 8 more
- Volunteers
- 914 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Unresectable Locally Advanced Pancreatic Carcinoma
A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel.
To evaluate the safety of OncoSil™ in a patient population undergoing standard chemotherapy treatment for pancreatic cancer. This study has been designed to satisfy FDA regulatory requirements.
- Trial name
- OncoPaC-1 (NCT03076216)
- Testing
- OncoSil™
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- OncoSil Medical Limited
Advanced Solid Tumors, Hepatocellular Carcinoma
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
An open-label, Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AST-3424 administered as a single agent
- Trial name
- NCT06239155
- Testing
- AST-3424
- Where
- 7 sites in China
- Volunteers
- 51 people
- Sponsor
- Ascentawits Pharmaceuticals, Ltd
Gastric Cancer, Gastro-esophageal Junction Cancer
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with…
- Conditions
- Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT06005493
- Testing
- AZD5863, AZD2936
- Where
- 25 sites in United States, China and 6 more
- Volunteers
- 392 people
- Sponsor
- AstraZeneca
Unspecified Adult Solid Tumor, Protocol Specific, Gastric Cancer
A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors
The primary objective of this study is to determine the maximum tolerated dose (MTD) of KX2-391 in Combination with paclitaxel in Phase I, and to evaluate the efficacy of KX2-391 in combination with paclitaxel in patients who are…
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific, Gastric Cancer, Breast Cancer
- Trial name
- NCT01764087
- Testing
- KX2-391 and Paclitaxel
- Where
- 2 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Non-small Cell Lung Cancer, Gastric Cancer
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
The purpose of this study is to evaluate the safety and tolerability of RO7496353 in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or…
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05867121
- Testing
- RO7496353, Atezolizumab, Capecitabine
- Where
- 27 sites in United States, Australia and 7 more
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.
Advanced Cancer, Metastatic Cancer
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
- Conditions
- Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma
- Trial name
- NCT05557045
- Testing
- JZP815
- Where
- 15 sites in United States
- Volunteers
- 98 people
- Sponsor
- Jazz Pharmaceuticals
Squamous Cell Lung Cancer, Gastric Cancer
Phase Ib Study of Oral R01 Monotherapy in Advanced Solid Tumors
This is a Phase I（Ib）, open-label, single-arm clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of R01 administered orally as monotherapy twice daily (BID) in patients…
- Conditions
- Squamous Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT07806500
- Testing
- R01
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing Anjianxi Bio-Medical Technology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.